Oct 10,2024

Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor

Senseonics Holdings, Inc. announced that its Eversense 365 continuous glucose monitoring (iCGM) system has been approved in the U.S. for adults with Type 1 and Type 2 diabetes. This next-generation system, now commercially launched by Ascensia Diabetes Care, allows for one year of continuous glucose monitoring with minimal interruptions, requiring only one calibration per week and no additional sensor replacements. The first patient to receive the Eversense 365 system is part of a collaboration with Mercy, a major healthcare provider, which expects about 30,000 of its patients could benefit from this technology. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve glycemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.

COLLABORATION PARTNERSHIP

#cgm

#institution

View Analyst & Ambassador Comments
Go to original news
Oct 07,2024

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 08,2024

Remote Patient Monitoring Market Poised for Rapid Growth (2024-2029)

The global Remote Patient Monitoring (RPM) market, valued at USD 39.54 billion in 2023, is expected to nearly double to USD 77.90 billion by 2029, growing at a CAGR of 11.97%. This surge is driven by the increasing prevalence of chronic diseases, an aging population, and post-COVID-19 healthcare investments in virtual care and home health monitoring. North America dominates the market, thanks to strategic partnerships, increased healthcare spending, and the rise of telehealth. Key players like Medtronic, Resmed, and Philips lead the highly competitive market. Emerging trends include AI integration, IoT-enabled devices, and non-invasive monitoring techniques, further enhancing patient care and early condition detection.

View Analyst & Ambassador Comments
Go to original news
Oct 08,2024

Henry Ford Health Launches New Company to Advance Population Health

Henry Ford Health has introduced a new non-profit subsidiary, Populance, aimed at improving population health. Populance helps doctors, hospitals, and health plans manage patient care more effectively by offering services that improve health outcomes and reduce costs. These services include care management, patient monitoring, and digital outreach tools to support physicians in caring for patients with chronic conditions like diabetes, hypertension, heart failure, and COPD.

View Analyst & Ambassador Comments
Go to original news
Oct 07,2024

Global Drug Device Combination Products Market is expected to reach revenue of USD 389.7 Bn by 2033, at 9.3% CAGR

The global Drug-Device Combination Products Market is projected to grow from USD 174.4 billion in 2024 to USD 389.7 billion by 2033, with a CAGR of 9.3%. This growth is fueled by advancements in drug delivery systems and the rising prevalence of chronic diseases like diabetes and cardiovascular conditions. Key products include drug-eluting stents, infusion pumps, transdermal patches, and inhalers. The U.S. market is expected to reach USD 125.6 billion by 2033, driven by new FDA approvals, innovative technologies, and an increased demand for less invasive and patient-tailored solutions. Infusion pumps and cardiovascular applications dominate the market, with hospitals as the leading end-users. Leading companies include Medtronic, Abbott Laboratories, and Boston Scientific. Technological advancements such as smart inhalers and automated insulin pumps are key trends, helping reduce non-compliance and improve patient outcomes.

View Analyst & Ambassador Comments
Go to original news
Oct 09,2024

Anne Beal, MD, MPH Joins Omada Health Board of Directors

Omada Health, the virtual between-visit healthcare provider, is proud to announce the addition of Anne Beal, MD, MPH, to Omada’s Board of Directors. “Dr. Beal has been a champion for integrating patient voices into research and advancing innovation centered on patient experience and clinical outcomes, which are key factors for sustainable market growth,” said Sean Duffy, CEO and Co-Founder of Omada Health. “We believe that her track record on the boards of both public and private companies, combined with her leadership roles at respected life sciences and non-profit organizations, will be a valuable addition to Omada as we scale our programs to serve diverse patient populations and address their evolving care needs.”

View Analyst & Ambassador Comments
Go to original news
Oct 01,2024

StrideMD Expands Strategic Partnerships to Enhance Diabetes Care and Remote Patient Monitoring

StrideMD, an innovator in remote patient monitoring for diabetes, has announced a series of strategic partnerships aimed at enhancing diabetes care and patient experiences. Key collaborations include a partnership with Dexcom, a leader in continuous glucose monitoring (CGM) technology, to provide real-time glucose monitoring, empowering patients with better control over their health and reducing complications. Additionally, StrideMD has teamed up with Advanced Diabetes Supply (ADS) to launch the StrideForward program, offering ADS members 24/7 access to endocrinologists and certified diabetes educators, thereby enhancing patient-centered care. The company is also integrating Assisted Intelligence Wellness’ AI-powered mirrors in its physician offices to improve patient experience and provide insights into overall wellness.

COLLABORATION PARTNERSHIP

#r&d

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 30,2024

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Oct 01,2024

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING

Glucotrack, Inc. has announced that it will present updated preclinical data for its continuous blood glucose monitor (CBGM) at the 24th Annual Diabetes Technology Meeting from October 15-17, 2024, in Burlingame, California. The meeting will showcase advancements in diabetes technology, including automated insulin delivery systems and innovations in continuous glucose monitoring. Mark Tapsak, PhD, will deliver an oral presentation titled “The Technology Behind Continuous Blood Glucose Monitoring,” highlighting the CBGM’s ability to measure glucose levels accurately in real-time without the lag associated with traditional interstitial glucose measurements. This novel technology aims to provide a less intrusive experience for diabetes management, eliminating the need for an on-body wearable. Additionally, two poster presentations will discuss the in vivo evaluation of the CBGM in chronic models. For more information, visit Glucotrack's website.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 01,2024

Eversense 365 Launches in the US: One Year. One CGM.

Ascensia Diabetes Care has launched the Eversense® 365 continuous glucose monitoring (CGM) system, the world’s first One Year CGM, designed to minimize device frustrations for individuals with diabetes. Cleared by the FDA for adults with type 1 and type 2 diabetes, the Eversense 365 allows users to monitor their glucose levels accurately for a full year with only one sensor replacement, reducing the hassle of frequent CGM interruptions common with traditional devices. Users can pay as little as $199 out of pocket for this year-long service, making it accessible for many. The device aims to enhance the quality of life for users by providing reliable alerts and reducing diabetes-related stress, enabling them to focus on their well-being rather than their monitoring technology. Eversense ambassador Troy Ita emphasized how this innovation significantly lessens the burden of managing diabetes, allowing individuals to prioritize family and other important aspects of life.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES